TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Control Bionics Ltd. ( (AU:CBL) ) has shared an announcement.
Control Bionics Limited has announced its U.S. subsidiary’s agreement to acquire the remaining shares of Neuro Elite Athletics, the company behind the NeuroBounce program, for $389,150. This acquisition aims to integrate NeuroBounce with Control Bionics’ NeuroStrip EMG technology, enhancing their presence in high-growth performance markets and accelerating innovation in athletic performance and rehabilitation.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
More about Control Bionics Ltd.
Control Bionics is a medical device company with over 20 years of experience in developing surface Electromyography (EMG) devices. Their core technology, NeuroNode, is a wireless wearable device that detects brain signals to skeletal muscles, enabling computer-controlled functions. They are also commercializing the NeuroStrip, a miniaturized EMG device aimed at markets like health diagnostics and sports performance. Control Bionics operates in North America, Australia, Singapore, and Japan.
Average Trading Volume: 1,076,238
Technical Sentiment Signal: Buy
Current Market Cap: A$24.39M
Learn more about CBL stock on TipRanks’ Stock Analysis page.